Artisan Partners Limited Partnership Lowers Position in Nurix Therapeutics, Inc. $NRIX

Artisan Partners Limited Partnership decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 580,749 shares of the company's stock after selling 57,860 shares during the period. Artisan Partners Limited Partnership owned about 0.76% of Nurix Therapeutics worth $6,615,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company's stock worth $6,029,000 after acquiring an additional 44,002 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Nurix Therapeutics by 84.1% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,391,638 shares of the company's stock valued at $15,851,000 after purchasing an additional 635,668 shares during the period. ARK Investment Management LLC boosted its stake in Nurix Therapeutics by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,590,910 shares of the company's stock worth $18,900,000 after purchasing an additional 60,617 shares during the period. Vanguard Group Inc. raised its stake in Nurix Therapeutics by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company's stock valued at $52,452,000 after acquiring an additional 69,856 shares during the last quarter. Finally, Vestal Point Capital LP lifted its holdings in shares of Nurix Therapeutics by 132.1% during the first quarter. Vestal Point Capital LP now owns 1,125,552 shares of the company's stock worth $13,372,000 after purchasing an additional 640,552 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NRIX. Needham & Company LLC reissued a "buy" rating and set a $26.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, November 4th. Piper Sandler decreased their price target on shares of Nurix Therapeutics from $35.00 to $32.00 and set an "overweight" rating for the company in a research report on Friday, October 10th. Morgan Stanley cut their price objective on shares of Nurix Therapeutics from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Tuesday, October 14th. Wall Street Zen downgraded shares of Nurix Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday, October 11th. Finally, Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $22.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $26.67.

Read Our Latest Analysis on NRIX

Nurix Therapeutics Stock Performance

NRIX opened at $16.76 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $23.00. The stock has a 50-day moving average of $10.85 and a 200-day moving average of $10.86. The company has a market cap of $1.29 billion, a PE ratio of -5.64 and a beta of 2.30.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.19). The company had revenue of $7.89 million for the quarter, compared to the consensus estimate of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,284 shares of the firm's stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the transaction, the chief financial officer directly owned 37,592 shares of the company's stock, valued at approximately $472,155.52. This trade represents a 14.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 4,087 shares of the business's stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $12.80, for a total value of $52,313.60. Following the completion of the transaction, the insider directly owned 76,751 shares of the company's stock, valued at approximately $982,412.80. The trade was a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,501 shares of company stock valued at $171,305 over the last three months. Company insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Stories

• Five stocks we like better than Nurix Therapeutics
• Differences Between Momentum Investing and Long Term Investing
• A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
• Why Are These Companies Considered Blue Chips?
• 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
• What is diluted earnings per share (Diluted EPS)?
• Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nurix Therapeutics Right Now?

Before you consider Nurix Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nurix Therapeutics wasn't on the list.

While Nurix Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here